Skip to main content

Release of engineered extracellular vesicles for delivery of biotherapeutics

Project description

Creating in situ drug "factories" for the delivery of biotherapeutics

Nucleic acid therapeutics represent an emerging treatment for unmet medical needs, targeting disease at the genetic level by preventing the expression of disease-causing proteins. One of their characteristics is that they need to be encapsulated in nanocarriers to ensure stability and efficient uptake into cells. A promising nanocarrier for drug delivery is extracellular vesicles (EV), which benefit from immune tolerance as native nanoparticles, and they are also able to cross biological barriers, including the blood–brain barrier. The EU-funded DELIVER project aims to develop synthetic nanocarriers to transiently engineer hepatic cells in vivo and turn them into specific EV-producing "factories" to deliver biotherapeutics to currently unreachable organs. The long-term project goal is to create a platform for in situ EV engineering, enabling the delivery of virtually any biotherapeutic product.

Call for proposal

ERC-2020-COG
See other projects for this call

Host institution

KAROLINSKA INSTITUTET
Address
Nobels Vag 5
17177 Stockholm
Sweden

See on map

Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 000 000

Beneficiaries (1)

KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 2 000 000
Address
Nobels Vag 5
17177 Stockholm

See on map

Activity type
Higher or Secondary Education Establishments